Pancreatic islet (of Langerhans) revisited

Carlos A. Mandarim-de-Lacerda

Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of Biology, The University of the State of Rio de Janeiro, Brazil

Offprint requests to: Dr. Carlos A. Mandarim-deLacerda, Laboratório de Morfometria, Metabolismo e Doencas Cardiovascular, Centro Biomédico, Instituto de Biologia, Universidade do Estado do Rio de Janeiro, UERJ, Brazil. e-mail: mandarim@uerj.br or mandarim.ca@gmail.com

Summary. One hundred and fifty years ago, Paul Langerhans described what would come to be known as pancreatic 'islet of Langerhans'. Since then, we have accumulated knowledge about the pancreatic islet, the cells that exist there and the hormones secreted by these cells. The increasing prevalence of obesity, diabetes and Alzheimer's disease in the population (three conditions that are linked to pancreatic islet function), the islet has been playing a significant role in endocrinological and metabolic studies searching how we can protect the pancreatic islet and its cell content, or how we can regenerate it. This review will be interested in the most recent and relevant aspects of knowledge regarding the pancreatic islet, always mentioning the evolution of knowledge and future perspectives for the treatment of diabetes and Alzheimer's disease. The most recent research with microRNAs and islet culture and pseudoislet culture (organoids) allows predicting advances in knowledge with new drugs to act on the islet/cells (such as the hormone glucagon-like peptide (GLP) -1) as well as induction of other islet cells like alpha-cells and delta-cells to transform into beta-cells. Histol Histopathol 34, 985-993 (2019)

Key words: Alpha-cell, Beta-cell, Delta-cell, Epsilon-cell, PP-cell

DOI: 10.14670/HH-18-118